182 related articles for article (PubMed ID: 19955801)
21. Tumor Control Probability Analysis for Single-Fraction Carbon-Ion Radiation Therapy of Early-Stage Non-small Cell Lung Cancer.
Paz AE; Yamamoto N; Sakama M; Matsufuji N; Kanai T
Int J Radiat Oncol Biol Phys; 2018 Dec; 102(5):1551-1559. PubMed ID: 30076985
[TBL] [Abstract][Full Text] [Related]
22. Should stereotactic body radiotherapy doses be adjusted according to tumor size in early-stage non-small-cell lung cancer? A systematic review and meta-analysis.
Luo H; Cui Y; Song H; Mao R; Gao Q; Ge H
Future Oncol; 2019 Sep; 15(26):3071-3079. PubMed ID: 31426674
[No Abstract] [Full Text] [Related]
23. A modified hypoxia-based TCP model to investigate the clinical outcome of stereotactic hypofractionated regimes for early stage non-small-cell lung cancer (NSCLC).
Strigari L; Benassi M; Sarnelli A; Polico R; D'Andrea M
Med Phys; 2012 Jul; 39(7):4502-14. PubMed ID: 22830782
[TBL] [Abstract][Full Text] [Related]
24. Optimal dose and fraction number in SBRT of lung tumours: A radiobiological analysis.
Ruggieri R; Stavrev P; Naccarato S; Stavreva N; Alongi F; Nahum AE
Phys Med; 2017 Dec; 44():188-195. PubMed ID: 28130055
[TBL] [Abstract][Full Text] [Related]
25. The evolution of Radiation Therapy Oncology Group (RTOG) protocols for nonsmall cell lung cancer.
Byhardt RW
Int J Radiat Oncol Biol Phys; 1995 Jul; 32(5):1513-25. PubMed ID: 7635796
[TBL] [Abstract][Full Text] [Related]
26. Dose and fractionation concepts in the primary radiotherapy of non-small cell lung cancer.
Baumann M; Appold S; Petersen C; Zips D; Herrmann T
Lung Cancer; 2001 Sep; 33 Suppl 1():S35-45. PubMed ID: 11576706
[TBL] [Abstract][Full Text] [Related]
27. Applicability of the linear-quadratic formalism for modeling local tumor control probability in high dose per fraction stereotactic body radiotherapy for early stage non-small cell lung cancer.
Guckenberger M; Klement RJ; Allgäuer M; Appold S; Dieckmann K; Ernst I; Ganswindt U; Holy R; Nestle U; Nevinny-Stickel M; Semrau S; Sterzing F; Wittig A; Andratschke N; Flentje M
Radiother Oncol; 2013 Oct; 109(1):13-20. PubMed ID: 24183066
[TBL] [Abstract][Full Text] [Related]
28. Final results of the randomized phase III CHARTWEL-trial (ARO 97-1) comparing hyperfractionated-accelerated versus conventionally fractionated radiotherapy in non-small cell lung cancer (NSCLC).
Baumann M; Herrmann T; Koch R; Matthiessen W; Appold S; Wahlers B; Kepka L; Marschke G; Feltl D; Fietkau R; Budach V; Dunst J; Dziadziuszko R; Krause M; Zips D;
Radiother Oncol; 2011 Jul; 100(1):76-85. PubMed ID: 21757247
[TBL] [Abstract][Full Text] [Related]
29. Tumor Control and Toxicity for Common Stereotactic Body Radiation Therapy Dose-Fractionation Regimens in Stage I Non-Small Cell Lung Cancer.
Stephans KL; Woody NM; Reddy CA; Varley M; Magnelli A; Zhuang T; Qi P; Videtic GMM
Int J Radiat Oncol Biol Phys; 2018 Feb; 100(2):462-469. PubMed ID: 29353658
[TBL] [Abstract][Full Text] [Related]
30. High-dose, hyperfractionated, accelerated radiotherapy using a concurrent boost for the treatment of nonsmall cell lung cancer: unusual toxicity and promising early results.
King SC; Acker JC; Kussin PS; Marks LB; Weeks KJ; Leopold KA
Int J Radiat Oncol Biol Phys; 1996 Oct; 36(3):593-9. PubMed ID: 8948343
[TBL] [Abstract][Full Text] [Related]
31. Five-year Long-term Outcomes of Stereotactic Body Radiation Therapy for Operable Versus Medically Inoperable Stage I Non-small-cell Lung Cancer: Analysis by Operability, Fractionation Regimen, Tumor Size, and Tumor Location.
Schonewolf CA; Heskel M; Doucette A; Singhal S; Frick MA; Xanthopoulos EP; Corradetti MN; Friedberg JS; Pechet TT; Christodouleas JP; Levin W; Berman A; Cengel KA; Verma V; Hahn SM; Kucharczuk JC; Rengan R; Simone CB
Clin Lung Cancer; 2019 Jan; 20(1):e63-e71. PubMed ID: 30337269
[TBL] [Abstract][Full Text] [Related]
32. Treatment of inoperable stage III and IV non-small-cell lung cancer: the 'average' radiotherapist's point of view.
Plataniotis GA; Theofanopoulou MA
Onkologie; 2001 Aug; 24(4):333-9. PubMed ID: 11574760
[TBL] [Abstract][Full Text] [Related]
33. Inhibiting the aurora B kinase potently suppresses repopulation during fractionated irradiation of human lung cancer cell lines.
Sak A; Stuschke M; Groneberg M; Kübler D; Pöttgen C; Eberhardt WE
Int J Radiat Oncol Biol Phys; 2012 Oct; 84(2):492-9. PubMed ID: 22381900
[TBL] [Abstract][Full Text] [Related]
34. Canadian Phase III Randomized Trial of Stereotactic Body Radiotherapy Versus Conventionally Hypofractionated Radiotherapy for Stage I, Medically Inoperable Non-Small-Cell Lung Cancer - Rationale and Protocol Design for the Ontario Clinical Oncology Group (OCOG)-LUSTRE Trial.
Swaminath A; Wierzbicki M; Parpia S; Wright JR; Tsakiridis TK; Okawara GS; Kundapur V; Bujold A; Ahmed N; Hirmiz K; Kurien E; Filion E; Gabos Z; Faria S; Louie AV; Owen T; Wai E; Ramchandar K; Chan EK; Julian J; Cline K; Whelan TJ
Clin Lung Cancer; 2017 Mar; 18(2):250-254. PubMed ID: 27876603
[TBL] [Abstract][Full Text] [Related]
35. A retrospective analysis of survival outcomes for two different radiotherapy fractionation schedules given in the same overall time for limited stage small cell lung cancer.
Bettington CS; Tripcony L; Bryant G; Hickey B; Pratt G; Fay M
J Med Imaging Radiat Oncol; 2013 Feb; 57(1):105-12. PubMed ID: 23374562
[TBL] [Abstract][Full Text] [Related]
36. Hypofractionated palliative radiotherapy (17 Gy per two fractions) in advanced non-small-cell lung carcinoma is comparable to standard fractionation for symptom control and survival: a national phase III trial.
Sundstrøm S; Bremnes R; Aasebø U; Aamdal S; Hatlevoll R; Brunsvig P; Johannessen DC; Klepp O; Fayers PM; Kaasa S
J Clin Oncol; 2004 Mar; 22(5):801-10. PubMed ID: 14990635
[TBL] [Abstract][Full Text] [Related]
37. The Promising Treatment Schedule of Concurrent Chemoradiotherapy for Stage III Non-small Cell Lung Cancer: Alternative for Conventional Fractionation Using Mathematical Analysis.
Ueda Y; Suzuki O; Ohira S; Yagi M; Sumida I; Wada K; Inui S; Isono M; Miyazaki M; Ogawa K; Teshima T
Anticancer Res; 2020 Jul; 40(7):4095-4104. PubMed ID: 32620658
[TBL] [Abstract][Full Text] [Related]
38. Hypofractionation in non-small cell lung cancer (NSCLC): suggestions from modelling both acute and chronic hypoxia.
Ruggieri R
Phys Med Biol; 2004 Oct; 49(20):4811-23. PubMed ID: 15566177
[TBL] [Abstract][Full Text] [Related]
39. Radiation dose prescription for non-small-cell lung cancer according to normal tissue dose constraints: an in silico clinical trial.
van Baardwijk A; Bosmans G; Bentzen SM; Boersma L; Dekker A; Wanders R; Wouters BG; Lambin P; De Ruysscher D
Int J Radiat Oncol Biol Phys; 2008 Jul; 71(4):1103-10. PubMed ID: 18258382
[TBL] [Abstract][Full Text] [Related]
40. Dose-per-fraction escalation of accelerated hypofractionated three-dimensional conformal radiotherapy in locally advanced non-small cell lung cancer.
Kepka L; Tyc-Szczepaniak D; Bujko K
J Thorac Oncol; 2009 Jul; 4(7):853-61. PubMed ID: 19487965
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
